following an abbreviated submission:
zanamivir (Dectova®) is accepted for use within NHSScotland.
Indication under review: For the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when:
- the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or
- other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.
Zanamivir should be used in accordance with official guidance.
Unlicensed intravenous zanamivir was previously available in a compassionate use programme. A licensed medicine is now available.
Download detailed advice379KB (PDF)
Medicine details
- Medicine name:
- zanamivir (Dectova)
- SMC ID:
- SMC2204
- Indication:
Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: • The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or • Other anti-viral agents for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 December 2019